1203902-67-3
1203902-67-3
Chemical Structure
Epitinib
Synonym(s): HMPL-813
- CAS No.: 1203902-67-3
- Formula:C24H26N6O2
- Molecular Weight:430.50
IUPAC Name: 4-ethyl-N-(4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)piperazine-1-carboxamide
InChIKey: DQAZPZIYEOGZAF-UHFFFAOYSA-N
SMILES: O=C(N1CCN(CC)CC1)NC2=CC3=C(NC4=CC=CC(C#C)=C4)N=CN=C3C=C2OC
Biological Activity: Epitinib (HMPL-813) is a selective, orally active, blood-brain barrier-permeable EGFR tyrosine kinase inhibitor. Epitinib is applicable to research on EGFRT790M-positive non-small cell lung cancer with brain metastasis and advanced solid tumors[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Epitinib | 99.95% | Epitinib (HMPL-813) is a selective, orally active, blood-brain barrier-permeable EGFR tyrosine kinase inhibitor. Epitinib is applicable to research on EGFRT790M-positive non-small cell lung cancer with brain metastasis and advanced solid tumors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Zhou Q, et al. The safety profile of a selective EGFR TKI epitinib (HMPL-813) in patients with advanced solid tumors and preliminary clinical efficacy in EGFRm+ NSCLC patients with brain metastasis[J]. 2016.
- [2]. Zhou Q, et al. A Phase I Dose Expansion Study of Epitinib to Evaluate Efficacy and Safety in EGFR Mutation Positive (EGFRm+) NSCLC Patients with Brain Metastasis: Topic: Brain Meta[J]. Journal of Thoracic Oncology, 2017, 12(1): S932-S933.
